Evaluation of the effect of the carrier of polymorphic variants of the SLCO1B1 gene on efficacy and safety in patients during treatment with statins
Abstract
The number of patients receiving statins is increasing every year. Considering the need for life-long intake of drugs of this group, the problem of improving safety and efficacy of their use becomes especially important. There is a large amount of data on the influence of various genetic factors on the safety of statins and the frequency of side effects peculiar to this group of drugs, such as statin-induced myopathy and rhabdomyolysis. The article presents the long-term results of a study devoted to the evaluation of the effect of the carriage of various polymorphic variants of SLCO1B1 on the safety and efficacy of statin therapy in terms of long-term treatment outcomes.
About the Authors
N. A. Rumyantsev
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Yu. V. Olefir
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
V. G. Kukes
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Brugts JJ, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: 2376.
2. Romanov BK. Kal’tsievaya regulyatsiya aktivnosti lizosomal’nykh fermentov miokarda. Biomedical chemistry 2005; 51(6): 634–42 (in Russian).
3. Romanov BK, Toropova II, Kolesnikova EYu. Medication errors. Risk and drug safety 2014; 2 (3): 28–30 (in Russian).
4. Ruiz Maldonado JM, Lumbreras B, Muñoz Jimenez H, Navarrete Carranza JM, Anza Aguirrezabala I, Pastor-Valero M. A pilot study in a community pharmacy to determine the efficiency and the effectiveness of statin prescriptions. Aten Primaria 2015; 47(5): 294–300.
5. Leuschen J, Mortensen EM, Frei CR. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmology 2013; 131 (11): 1427–34.
6. Carr DF, O’Meara H, Jorgensen AL. SLCO1B1 genetic variant associated with statin- induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharamachol Ther 2013; 94(6): 695–771.
7. Solodun MV, Yakushin SS. Osobennosti gipolipidemicheskoy terapii atorvastatinom pri infarkte miokarda s pozitsiy personalizirovannoy meditsiny 2015; (1): 31–5 (in Russian).
8. Romodanovsky DP, Goryachev DV. Planning and evaluation of bioequivalence studies of rosuvastatin drug products. The Bulletin of the Scientific Centre for Expert Evalution of Medicinal Products 2017; 7 (3): 142–9.
9. Sychev DA. Rekomendatsii po primeneniyu farmakogeneticheskogo testirovaniya v klinicheskoy praktike. Kachestvennaya klinicheskaya praktika 2011; (1): 3–10 (in Russian).
Review
For citations:
Rumyantsev N.A., Olefir Yu.V., Kukes V.G. Evaluation of the effect of the carrier of polymorphic variants of the SLCO1B1 gene on efficacy and safety in patients during treatment with statins. Safety and Risk of Pharmacotherapy. 2017;5(4):170-173. (In Russ.)
Views:
1164
Email this article 